The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea

  • Baek, Seon Ha (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Hyunsuk (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Jeonghwan (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Dong Ki (Department of Internal Medicine, Seoul National University Hospital) ;
  • Oh, Kook-Hwan (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Yon Su (Department of Internal Medicine, Seoul National University Hospital) ;
  • Han, Jin Suk (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Joo, Kwon-Wook (Department of Internal Medicine, Seoul National University Hospital)
  • Received : 2012.08.14
  • Accepted : 2012.10.15
  • Published : 2014.01.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (proteinuria [PU] and renal insufficiency [RI]) and to investigate the relationship between PU and antitumor efficacy. Methods: We performed a retrospective review of medical records of patients who had received sunitinib for more than 3 months. Results: One hundred and fifty-five patients (mean age, $58.7{\pm}12.6$ years) were enrolled, and the mean baseline creatinine level was 1.24 mg/dL. PU developed in 15 of 111 patients, and preexisting PU was aggravated in six of 111 patients. Only one patient developed typical nephrotic syndrome. Following discontinuation of sunitinib, PU was improved in 12 of 17 patients but persisted in five of 17 patients. RI occurred in 12 of 155 patients, and the maximum creatinine level was 3.31 mg/dL. RI improved in two of 12 patients but persisted in 10 of 12 patients. Risk factors for PU were hypertension, dyslipidemia, and chronic kidney disease. Older age was a risk factor for RI. The median progression-free survival was significantly better for patients who showed PU. Conclusions: The incidence of RAEs associated with sunitinib was lower than those of previous reports. The severity of RAEs was mild to moderate, and partially reversible after cessation of sunitinib. We suggest that blood pressure, urinalysis, and renal function in patients receiving sunitinib should be monitored closely.

Keywords

References

  1. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly: a mini-review. Gerontology 2010;56:303-309. https://doi.org/10.1159/000262450
  2. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322-328. https://doi.org/10.1016/j.amjmed.2008.11.025
  3. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-113. https://doi.org/10.1016/j.mvr.2007.03.004
  4. Oudard S, Beuselinck B, Decoene J, Albers P. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011;37:178-184. https://doi.org/10.1016/j.ctrv.2010.08.005
  5. Rini BI, Garcia JA, Cooney MM, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010;28:e284-e285. https://doi.org/10.1200/JCO.2009.27.1759
  6. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9-17. https://doi.org/10.1080/02841860802314720
  7. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338. https://doi.org/10.1016/S0140-6736(06)69446-4
  8. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930. https://doi.org/10.1016/j.eururo.2007.11.037
  9. Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010;21:1618-1622. https://doi.org/10.1093/annonc/mdp603
  10. van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-2995. https://doi.org/10.1200/JCO.2007.11.5113
  11. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-82. https://doi.org/10.1097/CAD.0b013e3283161012
  12. Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol 2009;2:172-176. https://doi.org/10.1159/000241551
  13. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011;117:c312-c319. https://doi.org/10.1159/000319885
  14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. https://doi.org/10.1056/NEJMoa065044
  15. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
  16. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. https://doi.org/10.1038/sj.bjc.6605483
  17. National Cancer Institute. NCI Term Browser: common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]. Rockville (MD): National Cancer Institute, c2010 [cited 2010 Jun 14]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  19. Obhrai JS, Patel TV, Humphreys BD. The case/progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008;74:685-686. https://doi.org/10.1038/ki.2008.288
  20. Kim HW, Lim JH, Kim MY, et al. Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis. Nephrol Dial Transplant 2011;26:1173-1188. https://doi.org/10.1093/ndt/gfq610
  21. Kim HS, Hong MH, Kim K, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 2011;80:395-405. https://doi.org/10.1159/000330361
  22. Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009;4:121-133. https://doi.org/10.1007/s11523-009-0109-x
  23. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100:282-284. https://doi.org/10.1093/jnci/djm311
  24. Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24:673-675.
  25. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007;5:341-344. https://doi.org/10.1016/j.amjopharm.2007.12.011
  26. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682-685.
  27. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010;46:439-448. https://doi.org/10.1016/j.ejca.2009.11.001
  28. Szmit S, Langiewicz P, Zlnierek J, et al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2012;35:18-25. https://doi.org/10.1159/000329933
  29. Rini BI. Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 2010;8:415-416.
  30. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-394.
  31. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18:1117. https://doi.org/10.1093/annonc/mdm184
  32. Machado FG, Kuriki PS, Fujihara CK, et al. Chronic VEGF blockade worsens glomerular injury in the remnant kidney model. PLoS One 2012;7:e39580. https://doi.org/10.1371/journal.pone.0039580

Cited by

  1. Risks associated with sunitinib use and monitoring to improve patient outcomes vol.29, pp.1, 2014, https://doi.org/10.3904/kjim.2014.29.1.23
  2. Inhibition of the VEGF signalling pathway and glomerular disorders vol.30, pp.9, 2014, https://doi.org/10.1093/ndt/gfu368
  3. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma vol.77, pp.2, 2014, https://doi.org/10.1007/s00280-015-2942-1
  4. Dasatinib-induced nephrotic syndrome vol.57, pp.3, 2014, https://doi.org/10.3109/10428194.2015.1075020
  5. Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients vol.17, pp.12, 2014, https://doi.org/10.3390/ijms17122073
  6. Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma vol.47, pp.12, 2014, https://doi.org/10.1093/jjco/hyx161
  7. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report vol.19, pp.None, 2014, https://doi.org/10.1186/s12882-018-1074-3
  8. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report vol.12, pp.1, 2018, https://doi.org/10.1186/s13256-018-1597-z
  9. The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors vol.27, pp.1, 2014, https://doi.org/10.1177/1073274820977143
  10. Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma vol.9, pp.11, 2020, https://doi.org/10.1002/cam4.2910
  11. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib vol.14, pp.1, 2014, https://doi.org/10.1093/ckj/sfaa137
  12. Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers vol.22, pp.23, 2014, https://doi.org/10.3390/ijms222312629